Evidence map›Paper›PMID 17356196›Full record

ArticleNeurocritical care2007

Cerebral correlates of hyponatremia.

Barnett R Nathan

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Neurocritical care, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03000283 (Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03000283 phase1completednot on this mapstarted 2017, after this paper: background citation

Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study

TypeinterventionalSponsorJesse CorryRan2017 to 2019Enrolled7ConditionsCerebral Hemorrhage, Cerebral Edema, Intracerebral Hemorrhage, StrokeArmsConivaptan
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 55 citations in OpenAlex.

  1. Trial
  2. Article
  3. Observational
  4. Article
  5. Review
  6. Article
  7. Impact of perioperative hyponatremia in children: A narrative review.World journal of critical care medicine · 2014
    Review
  8. Sodium and fluid management in acute brain injury.Current neurology and neuroscience reports · 2012
    Review
  9. Intracranial hypertension secondary to psychogenic polydipsia.Journal of emergencies, trauma, and shock · 2012
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Barnett R NathanDepartment of Neurology, University of Virginia, Charlottesville, VA 22908, USA. brn3a@virginia.edu
University of Virginia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyponatremia, defined as a serum sodium concentration ([Na+]) less than 135 mEq/L, is commonly caused by elevated levels of the hormone arginine vasopressin (AVP), which causes water retention. The principal organ affected by disease-related morbidity is the brain. The neurologic complications associated with hyponatremia are attributable to cerebral edema and increased intracranial pressure, caused by the osmotically driven movement of water from the extracellular compartment into brain cells. Although neurologic symptoms induced by hyponatremia are limited by an adaptive brain mechanism known as "regulatory volume decrease," an overly rapid correction of serum [Na+] before the reversal of this adaptive response can also produce neurologic damage. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is a frequent cause of hyponatremia related to central nervous system disorders, neurosurgery, or the use of psychoactive drugs. Fluid restriction is the standard of care for patients with SIADH who are asymptomatic or who have only mild symptoms, but patients with severe or symptomatic hyponatremia require more aggressive therapy. Infusion of hypertonic saline is the usual approach to the treatment of symptomatic hyponatremia, but patients require frequent monitoring. Pharmacologic agents such as demeclocycline and lithium may be effective in some patients but are associated with undesirable adverse events. The AVPreceptor antagonists are a new therapeutic class for the treatment of hyponatremia. The first agent in this class approved for the treatment of euvolemic hyponatremia in hospitalized patients is conivaptan. Two other agents, tolvaptan and lixivaptan, are being evaluated in patients with euvolemic and hypervolemic hyponatremia. The AVP-receptor antagonists block the effects of elevated AVP and promote aquaresis, the electrolyte-sparing excretion of water, resulting in the correction of serum [Na+]. These agents may also have intrinsic neuroprotective effects.

Indexed as

Antidiuretic Hormone Receptor AntagonistsDiagnosis, DifferentialHumansHyponatremiaInappropriate ADH SyndromeMyelin SheathSodium ChlorideWasting SyndromeWater-Electrolyte BalanceAntidiuretic Hormone Receptor AntagonistsSodium Chloride

Identifiers

PMID17356196
OpenAlexW1967470449

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.